Biotech precision medicine drug developer Celsius Therapeutics has raised USD 83 million in total funding from an extension of a Series A funding round, previously announced in May 2018, and a Series B round. The company received funding from new and existing investors including Casdin Capital, GV, Heritage Provider Network, Amgen Ventures, and Amplitude Ventures.
The funds will be invested in its investigational new drug (IND) filing with the FDA for its first drug candidate CEL383, an antibody treatment for inflammatory bowel disease, followed by a Phase 1 clinical trial in early 2023. The funds will also support the company’s plans to expand its oncology pipeline using its SCOPE platform to discover drug targets.
Celsius currently has two drug discovery programs in oncology in partnership with independent pharma group Servier.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.